Annual EBIT
-$131.99 M
-$36.91 M-38.81%
April 30, 2024
Summary
- As of February 8, 2025, KALV annual earnings before interest & taxes is -$131.99 million, with the most recent change of -$36.91 million (-38.81%) on April 30, 2024.
- During the last 3 years, KALV annual EBIT has fallen by -$74.07 million (-127.88%).
- KALV annual EBIT is now -7245.19% below its all-time high of -$1.80 million, reached on December 31, 2012.
Performance
KALV EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$45.81 M
-$1.60 M-3.61%
October 31, 2024
Summary
- As of February 8, 2025, KALV quarterly earnings before interest & taxes is -$45.81 million, with the most recent change of -$1.60 million (-3.61%) on October 31, 2024.
- Over the past year, KALV quarterly EBIT has dropped by -$5.81 million (-14.52%).
- KALV quarterly EBIT is now -3887.03% below its all-time high of -$1.15 million, reached on December 31, 2013.
Performance
KALV Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$163.18 M
-$16.07 M-10.92%
October 31, 2024
Summary
- As of February 8, 2025, KALV TTM earnings before interest & taxes is -$163.18 million, with the most recent change of -$16.07 million (-10.92%) on October 31, 2024.
- Over the past year, KALV TTM EBIT has dropped by -$31.19 million (-23.63%).
- KALV TTM EBIT is now -14101.91% below its all-time high of -$1.15 million, reached on December 31, 2013.
Performance
KALV TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
KALV EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -38.8% | -14.5% | -23.6% |
| 3 y3 years | -127.9% | -94.1% | -121.1% |
| 5 y5 years | -342.6% | -393.2% | -280.9% |
KALV EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -127.9% | at low | -298.1% | at low | -100.7% | at low |
| 5 y | 5-year | -342.6% | at low | -411.4% | at low | -302.6% | at low |
| alltime | all time | -7245.2% | at low | -3887.0% | at low | <-9999.0% | at low |
KalVista Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2024 | - | -$45.81 M(+3.6%) | -$163.18 M(+10.9%) |
| Jul 2024 | - | -$44.22 M(+10.5%) | -$147.12 M(+11.5%) |
| Apr 2024 | -$131.99 M(+38.8%) | -$40.00 M(+20.7%) | -$131.99 M(+22.3%) |
| Jan 2024 | - | -$33.15 M(+11.4%) | -$107.93 M(+6.1%) |
| Oct 2023 | - | -$29.75 M(+2.2%) | -$101.73 M(+3.9%) |
| Jul 2023 | - | -$29.09 M(+82.5%) | -$97.86 M(+2.9%) |
| Apr 2023 | -$95.09 M(+16.9%) | -$15.94 M(-40.8%) | -$95.09 M(+4.9%) |
| Jan 2023 | - | -$26.95 M(+4.1%) | -$90.65 M(+0.3%) |
| Oct 2022 | - | -$25.88 M(-1.6%) | -$90.39 M(+2.6%) |
| Jul 2022 | - | -$26.32 M(+128.7%) | -$88.11 M(+8.4%) |
| Apr 2022 | - | -$11.51 M(-56.9%) | -$81.31 M(-7.4%) |
| Apr 2022 | -$81.31 M(+40.4%) | - | - |
| Jan 2022 | - | -$26.68 M(+13.0%) | -$87.84 M(+19.0%) |
| Oct 2021 | - | -$23.60 M(+20.9%) | -$73.82 M(+17.2%) |
| Jul 2021 | - | -$19.52 M(+8.2%) | -$63.00 M(+8.8%) |
| Apr 2021 | -$57.92 M(+42.9%) | -$18.04 M(+42.5%) | -$57.92 M(+18.6%) |
| Jan 2021 | - | -$12.66 M(-1.0%) | -$48.84 M(-0.1%) |
| Oct 2020 | - | -$12.78 M(-11.5%) | -$48.91 M(+7.7%) |
| Jul 2020 | - | -$14.44 M(+61.2%) | -$45.41 M(+12.0%) |
| Apr 2020 | -$40.53 M(+35.9%) | -$8.96 M(-29.6%) | -$40.53 M(-5.4%) |
| Jan 2020 | - | -$12.72 M(+37.0%) | -$42.84 M(+16.5%) |
| Oct 2019 | - | -$9.29 M(-2.9%) | -$36.77 M(+13.6%) |
| Jul 2019 | - | -$9.56 M(-15.1%) | -$32.38 M(+8.6%) |
| Apr 2019 | -$29.82 M | -$11.26 M(+69.1%) | -$29.82 M(+38.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jan 2019 | - | -$6.66 M(+36.1%) | -$21.53 M(+12.0%) |
| Oct 2018 | - | -$4.89 M(-30.2%) | -$19.22 M(-5.2%) |
| Jul 2018 | - | -$7.01 M(+136.1%) | -$20.26 M(+8.3%) |
| Apr 2018 | -$18.70 M(-16.3%) | -$2.97 M(-31.7%) | -$18.70 M(-10.2%) |
| Jan 2018 | - | -$4.35 M(-26.8%) | -$20.82 M(-15.3%) |
| Oct 2017 | - | -$5.94 M(+8.9%) | -$24.59 M(+16.9%) |
| Jul 2017 | - | -$5.45 M(+7.2%) | -$21.04 M(-6.6%) |
| Apr 2017 | -$22.34 M(+47.2%) | -$5.09 M(-37.3%) | -$22.53 M(-6.0%) |
| Jan 2017 | - | -$8.12 M(+240.3%) | -$23.96 M(+11.9%) |
| Sep 2016 | - | -$2.38 M(-65.7%) | -$21.42 M(-10.5%) |
| Jun 2016 | - | -$6.94 M(+6.5%) | -$23.93 M(-7.4%) |
| Apr 2016 | -$15.18 M(-35.8%) | - | - |
| Mar 2016 | - | -$6.52 M(+17.0%) | -$25.83 M(+9.2%) |
| Dec 2015 | -$23.66 M(+192.5%) | -$5.57 M(+13.8%) | -$23.66 M(+6.4%) |
| Sep 2015 | - | -$4.90 M(-44.6%) | -$22.24 M(+6.0%) |
| Jun 2015 | - | -$8.84 M(+103.4%) | -$20.98 M(+42.8%) |
| Apr 2015 | -$8.09 M(-34.1%) | - | - |
| Mar 2015 | - | -$4.35 M(+4.7%) | -$14.69 M(+19.7%) |
| Dec 2014 | -$12.28 M(+132.8%) | -$4.15 M(+14.1%) | -$12.28 M(+32.4%) |
| Sep 2014 | - | -$3.64 M(+42.6%) | -$9.27 M(+64.5%) |
| Jun 2014 | - | -$2.55 M(+31.9%) | -$5.64 M(+82.7%) |
| Mar 2014 | - | -$1.94 M(+68.4%) | -$3.08 M(+168.4%) |
| Dec 2013 | -$5.27 M(+193.4%) | -$1.15 M | -$1.15 M |
| Dec 2012 | -$1.80 M | - | - |
FAQ
- What is KalVista Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals annual EBIT year-on-year change?
- What is KalVista Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals quarterly EBIT year-on-year change?
- What is KalVista Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for KalVista Pharmaceuticals?
- What is KalVista Pharmaceuticals TTM EBIT year-on-year change?
What is KalVista Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of KALV is -$131.99 M
What is the all time high annual EBIT for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high annual earnings before interest & taxes is -$1.80 M
What is KalVista Pharmaceuticals annual EBIT year-on-year change?
Over the past year, KALV annual earnings before interest & taxes has changed by -$36.91 M (-38.81%)
What is KalVista Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of KALV is -$45.81 M
What is the all time high quarterly EBIT for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high quarterly earnings before interest & taxes is -$1.15 M
What is KalVista Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, KALV quarterly earnings before interest & taxes has changed by -$5.81 M (-14.52%)
What is KalVista Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of KALV is -$163.18 M
What is the all time high TTM EBIT for KalVista Pharmaceuticals?
KalVista Pharmaceuticals all-time high TTM earnings before interest & taxes is -$1.15 M
What is KalVista Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, KALV TTM earnings before interest & taxes has changed by -$31.19 M (-23.63%)